Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Legnani, C
Right arrow Articles by Palareti, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Legnani, C
Right arrow Articles by Palareti, G
Haematologica, Vol 89, Issue 11, 1347-1351
Copyright © 2004 by Ferrata Storti Foundation


Journal Article

Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels

C Legnani, M Cini, B Cosmi, M Poggi, O Boggian, and G Palareti

Dept. Angiology & Blood Coagulation Marino Golinelli, University Hospital S. Orsola-Malpighi, via Massarenti, 9 40138 Bologna, Italy. legnani@orsola-malpighi.med.unibo.it

BACKGROUND AND OBJECTIVES: High levels of factor VIII are a common risk factor for venous thromboembolism (VTE). The aim of this study was to evaluate the possible interaction between the presence of high factor VIII levels and oral contraceptive (OC) use. DESIGN AND METHODS: Factor VIII levels were measured by a chromogenic assay in 174 women who suffered from VTE in reproductive age and in 484 healthy women. Subjects carrying thrombophilic alterations were excluded. RESULTS: Factor VIII levels were stratified into quartiles. The adjusted odds ratio (OR) of VTE in subjects with factor VIII levels in the upper quartile (>1.95 IU/mL) was 7.45 (95%CI: 3.80-14.6). Among the 174 patients, 85 had experienced VTE during OC use. The 179 healthy women who had used OC for at least 6 months in the two years before presentation but had stopped OC at least 3 months before the blood sampling were considered as OC users. The risk of VTE among OC users with factor VIII levels in the upper quartile was increased about 13-fold (OR: 13.0, 95% CI: 4.92-34.3). INTERPRETATION AND CONCLUSIONS: Our results showed that there is an increased risk of VTE due to oral contraceptive use in women with elevated factor VIII and, as has been previously described for factor V Leiden and G20210A prothrombin mutations, the raised level of the coagulation factor and oral contraceptive use seem to have a synergistic effect.


This article has been cited by other articles:


Home page
JBJSHome page
C. J. Glueck, R. A. Freiberg, S. Boppana, and P. Wang
Thrombophilia, Hypofibrinolysis, the eNOS T-786C Polymorphism, and Multifocal Osteonecrosis
J. Bone Joint Surg. Am., October 1, 2008; 90(10): 2220 - 2229.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Sitruk-Ware, G. Plu-Bureau, J. Menard, J. Conard, S. Kumar, J.-C. Thalabard, B. Tokay, and P. Bouchard
Effects of Oral and Transvaginal Ethinyl Estradiol on Hemostatic Factors and Hepatic Proteins in a Randomized, Crossover Study
J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2074 - 2079.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.